265 related articles for article (PubMed ID: 20800019)
21. Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry.
Naz E; Mirza T; Danish F
Asian Pac J Cancer Prev; 2011; 12(12):3335-9. PubMed ID: 22471476
[TBL] [Abstract][Full Text] [Related]
22. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
23. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
[TBL] [Abstract][Full Text] [Related]
25. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
[TBL] [Abstract][Full Text] [Related]
26. The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.
Lu TX; Miao Y; Wu JZ; Gong QX; Liang JH; Wang Z; Wang L; Fan L; Hua D; Chen YY; Xu W; Zhang ZH; Li JY
Sci Rep; 2016 Feb; 6():20465. PubMed ID: 26857366
[TBL] [Abstract][Full Text] [Related]
27. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
Zeng LP; Wen YL; Ma Y; Wang GQ; Li Y; Wang J; Xu LL; Zhang XM
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
Oh S; Koo DH; Suh C; Kim S; Park BH; Kang J; Huh J
J Korean Med Sci; 2011 Dec; 26(12):1556-62. PubMed ID: 22147991
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma.
Alacacioglu I; Ozcan MA; Ozkal S; Piskin O; Turgut N; Demirkan F; Ozsan GH; Kargi A; Undar B
Hematology; 2009 Apr; 14(2):84-9. PubMed ID: 19298719
[TBL] [Abstract][Full Text] [Related]
30. Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma.
Chung KM; Chang ST; Huang WT; Lu CL; Wu HC; Hwang WS; Chang KY; Chuang SS
J Formos Med Assoc; 2013 Jul; 112(7):382-9. PubMed ID: 23927977
[TBL] [Abstract][Full Text] [Related]
31. The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas.
Rayman N; Lam KH; van der Holt B; Koss C; van Leeuwen J; Budel LM; Mulder AH; Sonneveld P; Delwel R
Eur J Haematol; 2011 Jun; 86(6):466-76. PubMed ID: 21457344
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful.
Martin-Arruti M; Vaquero M; Díaz de Otazu R; Zabalza I; Ballesteros J; Roncador G; García-Orad A
Histopathology; 2012 Apr; 60(5):785-92. PubMed ID: 22321048
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.
Dwivedi A; Mehta A; Solanki P
Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066
[TBL] [Abstract][Full Text] [Related]
35. Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma.
Zizhen Z; Hui C; Yanying S; Danping S; Jiahua L; Chao H; Xingzhi N
Pathol Oncol Res; 2013 Apr; 19(2):317-22. PubMed ID: 23239192
[TBL] [Abstract][Full Text] [Related]
36. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
37. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Delabie J; Ott G; Müller-Hermelink HK; Campo E; Braziel RM; Jaffe ES; Pan Z; Farinha P; Smith LM; Falini B; Banham AH; Rosenwald A; Staudt LM; Connors JM; Armitage JO; Chan WC
Blood; 2004 Jan; 103(1):275-82. PubMed ID: 14504078
[TBL] [Abstract][Full Text] [Related]
38. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
[TBL] [Abstract][Full Text] [Related]
39. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
[TBL] [Abstract][Full Text] [Related]
40. [Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].
Yu BH; Zhou XY; Xiao XY; Yan SY; Qin T; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):35-41. PubMed ID: 19489223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
